Related Experiment Video
Updated: Sep 17, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
DNA methylation protects cancer cells against senescence
Xiaoying Chen1, Kosuke Yamaguchi2,3, Brianna Rodgers1
1Université Paris Cité, CNRS, Epigenetics and Cell Fate, Paris, France.
Abstract:
Inhibitors of DNA methylation such as 5-aza-deoxycytidine are widely used in experimental and clinical settings. However, their mechanism of action is such that DNA damage inevitably co-occurs with loss of DNA methylation, making it challenging to discern their respective effects. Here we deconvolute the effects of decreased DNA methylation and DNA damage on cancer cells, by using degron alleles of key DNA methylation regulators. We report that cancer cells with decreased DNA methylation-but no DNA damage-enter cellular senescence, with G1 arrest, SASP expression, and SA-β-gal positivity. This senescence is independent of p53 and Rb, but involves p21, which is cytoplasmic and inhibits apoptosis, and cGAS, playing a STING-independent role in the nucleus. Xenograft experiments show that tumor cells can be made senescent in vivo by decreasing DNA methylation. These findings reveal the intrinsic effects of loss of DNA methylation in cancer cells and have practical implications for future therapeutic approaches.
Insights
Decreasing DNA methylation in cancer cells induces senescence, characterized by cell cycle arrest and specific molecular markers. This occurs independently of DNA damage, offering new therapeutic strategies.
Area of Science:
- Oncology
- Epigenetics
- Cellular Biology
Background:
- DNA methylation inhibitors like 5-aza-deoxycytidine are used in cancer research and treatment.
- Disentangling the effects of DNA methylation loss from DNA damage caused by these inhibitors is difficult.
Purpose of the Study:
- To differentiate the effects of reduced DNA methylation from DNA damage in cancer cells.
- To investigate the cellular and in vivo consequences of decreased DNA methylation.
Main Methods:
- Utilized degron alleles of DNA methylation regulators to separate DNA methylation loss from DNA damage.
- Assessed cancer cell responses including cell cycle arrest, senescence-associated secretory phenotype (SASP), and senescence markers.
- Conducted xenograft experiments to evaluate in vivo effects.
Main Results:
- Cancer cells with reduced DNA methylation but no DNA damage exhibited hallmarks of cellular senescence, including G1 arrest, SASP, and SA-β-gal positivity.
- This senescence was independent of p53 and Rb but involved cytoplasmic p21 and nuclear, STING-independent cGAS.
- In vivo xenograft studies demonstrated that decreasing DNA methylation can induce tumor cell senescence.
Conclusions:
- Loss of DNA methylation intrinsically induces cellular senescence in cancer cells, independent of DNA damage.
- p21 and cGAS play key roles in this novel senescence pathway.
- Targeting DNA methylation to induce senescence presents a promising therapeutic avenue in oncology.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Replicative Cell Senescence
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
Overview of DNA Repair
Chemically...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

